Quest (Celera) has noted that there is growing support for a lung cancer screening
program in the USA with recommendation from the US Preventative Screening Task
Force (December 2013). Their estimate for the target market of the test is 7 million
people annually, who are at high risk for lung cancer.
Quest (Celera) has until 31 October 2014 to commercialise their lung cancer blood
test with MK included, after which they maintain their ability to use MK, but will lose
exclusivity under the terms of the license agreement.
- Forums
- ASX - By Stock
- AN1
- 234 still a sell
234 still a sell, page-4
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AN1 (ASX) to my watchlist
|
|||||
Last
0.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $3.690M |
Open | High | Low | Value | Volume |
0.8¢ | 0.8¢ | 0.8¢ | $336 | 42K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 1457234 | 0.8¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.9¢ | 340000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 1457234 | 0.008 |
2 | 1111500 | 0.007 |
4 | 1006527 | 0.006 |
1 | 300000 | 0.005 |
2 | 525000 | 0.004 |
Price($) | Vol. | No. |
---|---|---|
0.009 | 340000 | 1 |
0.011 | 100000 | 1 |
0.012 | 100000 | 1 |
0.013 | 750000 | 1 |
0.015 | 440000 | 3 |
Last trade - 14.19pm 12/07/2024 (20 minute delay) ? |
Featured News
AN1 (ASX) Chart |